Seegene European Society of Clinical Microbiology Releases Video of a Fully Automatic PCR Unmanned Test System
Apr 09, 2025
The European Society of Clinical Microbiological Infections (ESCMID Global 2025), which will be held in Vienna, Austria from the 11th to the 15th (local time), will be released with the CURECA™ video currently being developed. It is the first time to present an introductory video before the actual release in July.
'ESCMID Global 2025' is Europe's largest annual clinical microorganism and infectious disease conference on the latest diagnosis and treatment of infectious diseases, new infectious diseases, infectious disease control, and drug resistance. As the market for in vitro diagnostic tests, including molecular diagnostics, grows every year, the number of participants has also increased, with 249 companies and more than 18,000 experts participating last year. Since 2007, Seegene has participated every year to introduce products with syndrome quantitative PCR technology and innovative test solutions.
CURECA™ is the first letter of 'Continuous Unlimited Random Access Expandable and Customizable Full Automation' and is Seegene's next-generation diagnostic system that can automatically test all PCR (Polymerase Chain Reaction, hereinafter referred to as PCR) samples without going through human hands.
It consists of two parts: a sample automatic pre-processing device (CPS) and a test equipment (CEFA) that performs gene amplification and result analysis from nucleic acid extraction.
As the pre-processing process of molecular diagnosis requires classification of various samples and containers of various specifications such as ▲ stool ▲ urine ▲ blood ▲ sputum, many experts in the laboratory take time to conduct it manually.
Accordingly, Seegene is attempting to automate the preprocessing of all PCR samples for the first time in the world. CPS currently under development can also handle centrifugation and heat treatment processes after specimen classification. In addition, if the user separates CPS from the entire system, CURECA™, it can be used for pretreatment in other diagnostic fields such as ▲ diagnostic blood ▲ biochemical ▲ immunity, other than molecular diagnosis.
CURECA™, which operates unattended, can fundamentally block human errors that inevitably occur during the inspection process. It is designed with modular equipment, so customized setting is possible according to the needs of each laboratory. As a result, mass inspections are expected to be possible 24 hours without any restriction on equipment operation time or working hours of inspection personnel in the inspection room.
The CURECA™ video released by Seegene shows the entire PCR test process, which leads to specimen loading → sample pre-processing → nucleic acid extraction → PCR setup → gene amplification → result analysis, and the configuration of a customized system according to the laboratory environment. The actual product of CURECA™ will be unveiled at the world's largest exhibition on diagnostic testing, the American Society of Diagnostic Test Medicine (ADLM) 2025, to be held in Chicago, USA at the end of July.
Chun Jong-yoon, CEO of Seegene, said "As we don't have any equipment to automatically preprocess all kinds of samples yet, practical automation of molecular diagnosis has not been achieved."In addition to Seegene's proprietary syndrome quantitative PCR diagnostic reagent, CURECA™ will be the new benchmark for global molecular diagnostics in the future and we expect the diagnostic paradigm to change completely." In order for the technology sharing business to spread and a disease-free world to be realized, the global popularization and dailyization of molecular diagnostics are essential, but there are points to be overcome, such as inconvenience and high cost during the inspection process"CURECA™ is the best and ultimate item to solve these problems at once," he added.
In addition to the release of the CURECA™ video at ESCMID, Seegene will operate an exhibition booth under the theme of 「Examination Solution」 to introduce a portfolio of diagnostic reagents applying syndrome quantitative PCR technology, while also conducting a symposium dealing with topics that are currently emerging as major issues in the diagnostic industry. The symposium will introduce representative products related to Seegene's drug resistance test (Entero DR, STI-AMR, etc.) under the theme of 'Role and usefulness of molecular diagnosis in post-COVID antibiotic resistance issues'.
'ESCMID Global 2025' is Europe's largest annual clinical microorganism and infectious disease conference on the latest diagnosis and treatment of infectious diseases, new infectious diseases, infectious disease control, and drug resistance. As the market for in vitro diagnostic tests, including molecular diagnostics, grows every year, the number of participants has also increased, with 249 companies and more than 18,000 experts participating last year. Since 2007, Seegene has participated every year to introduce products with syndrome quantitative PCR technology and innovative test solutions.
|
It consists of two parts: a sample automatic pre-processing device (CPS) and a test equipment (CEFA) that performs gene amplification and result analysis from nucleic acid extraction.
As the pre-processing process of molecular diagnosis requires classification of various samples and containers of various specifications such as ▲ stool ▲ urine ▲ blood ▲ sputum, many experts in the laboratory take time to conduct it manually.
Accordingly, Seegene is attempting to automate the preprocessing of all PCR samples for the first time in the world. CPS currently under development can also handle centrifugation and heat treatment processes after specimen classification. In addition, if the user separates CPS from the entire system, CURECA™, it can be used for pretreatment in other diagnostic fields such as ▲ diagnostic blood ▲ biochemical ▲ immunity, other than molecular diagnosis.
CURECA™, which operates unattended, can fundamentally block human errors that inevitably occur during the inspection process. It is designed with modular equipment, so customized setting is possible according to the needs of each laboratory. As a result, mass inspections are expected to be possible 24 hours without any restriction on equipment operation time or working hours of inspection personnel in the inspection room.
The CURECA™ video released by Seegene shows the entire PCR test process, which leads to specimen loading → sample pre-processing → nucleic acid extraction → PCR setup → gene amplification → result analysis, and the configuration of a customized system according to the laboratory environment. The actual product of CURECA™ will be unveiled at the world's largest exhibition on diagnostic testing, the American Society of Diagnostic Test Medicine (ADLM) 2025, to be held in Chicago, USA at the end of July.
Chun Jong-yoon, CEO of Seegene, said "As we don't have any equipment to automatically preprocess all kinds of samples yet, practical automation of molecular diagnosis has not been achieved."In addition to Seegene's proprietary syndrome quantitative PCR diagnostic reagent, CURECA™ will be the new benchmark for global molecular diagnostics in the future and we expect the diagnostic paradigm to change completely." In order for the technology sharing business to spread and a disease-free world to be realized, the global popularization and dailyization of molecular diagnostics are essential, but there are points to be overcome, such as inconvenience and high cost during the inspection process"CURECA™ is the best and ultimate item to solve these problems at once," he added.
In addition to the release of the CURECA™ video at ESCMID, Seegene will operate an exhibition booth under the theme of 「Examination Solution」 to introduce a portfolio of diagnostic reagents applying syndrome quantitative PCR technology, while also conducting a symposium dealing with topics that are currently emerging as major issues in the diagnostic industry. The symposium will introduce representative products related to Seegene's drug resistance test (Entero DR, STI-AMR, etc.) under the theme of 'Role and usefulness of molecular diagnosis in post-COVID antibiotic resistance issues'.
This article was translated by Naver AI translator.
